{
    "clinical_study": {
        "@rank": "146121", 
        "arm_group": [
            {
                "arm_group_label": "Pregabaline", 
                "arm_group_type": "Experimental", 
                "description": "Groups PREGABALINE : 150 mg de LYRICA\u00ae"
            }, 
            {
                "arm_group_label": "Hydroxyzine", 
                "arm_group_type": "Experimental", 
                "description": "Groups HYDROXYZINE : 75 mg d'ATARAX\u00ae"
            }, 
            {
                "arm_group_label": "Lactose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Groups placebo : 4 g de lactose"
            }
        ], 
        "brief_summary": {
            "textblock": "The insertion of long-lasting intravenous device is  done under local anesthesia. Currently,\n      in the investigators hospital, no premedication is given to the patients. However, this\n      procedure occurs in a particular emotional context related to the diagnosis of cancer or\n      malign hemopathies.\n\n      Therefore, administration of a sedative or anxiolytic drugs before the start of the\n      procedure can be questionable.\n\n      Hydroxyzine is the reference molecule for premedication because of its anxiolytic and\n      anti-histaminic properties A new agent, pregabalin, shares also the same properties\n\n      The main objective of this study was to compare the efficacy of pregabalin and hydroxyzine\n      on the anxiety score as a premedication during the insertion of  long-lasting intravenous\n      device under local anesthesia."
        }, 
        "brief_title": "Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score", 
        "condition": "Feeling Anxious", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged from 18 to 75 years\n\n          -  Patient schedules for insertion of long-lasting intravenous device\n\n        Exclusion Criteria:\n\n          -  History of previous insertion of long-lasting intravenous device or central\n             intravenous catheter\n\n          -  long term treatment of gabapentin or pregabalin\n\n          -  Hypersensitivity to pregabalin or any of the excipients\n\n          -  Hypersensitivity to hydroxyzine, one of its metabolites, one of the excipients,\n             another derivative of piperazine, aminophylline or ethylene diamine.\n\n          -  Patient at risk of glaucoma e\n\n          -  Patient at risk for urinary retention\n\n          -  Patient severe respiratory failure\n\n          -  Patient at the general condition not too corrupted (ASA IV)\n\n          -  Renal failure with creatinin clearance < 30 ml / min\n\n          -  Patient not affiliated to Social Security\n\n          -  Pregnant or lactating\n\n          -  Patients in emergency situations\n\n          -  Inpatient without consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675986", 
            "org_study_id": "GABAPAC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hydroxyzine", 
                "description": "75 mg", 
                "intervention_name": "hydroxyzine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pregabaline", 
                "description": "150 mg", 
                "intervention_name": "Pregabalin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lactose", 
                "description": "4 g", 
                "intervention_name": "Lactose", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydroxyzine", 
                "Pregabalin"
            ]
        }, 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "contact": {
                "last_name": "Bertrand Debaene", 
                "phone": "0549443895"
            }, 
            "facility": {
                "address": {
                    "city": "Poitiers", 
                    "country": "France", 
                    "zip": "86021"
                }, 
                "name": "CHU de POITIERS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "overall_contact": {
            "email": "bertrand.debaene@chu-poitiers.fr", 
            "last_name": "Bertrand DEBAENE, MD", 
            "phone": "0549443895"
        }, 
        "overall_official": {
            "affiliation": "Poitiers University Hospital", 
            "last_name": "Bertrand DEBAENE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "anxiety score VAS: 0 to 100", 
            "measure": "Efficacy treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "anxiety score VAS:0 to 100", 
            "measure": "Efficacy of pregabaldin"
        }, 
        "source": "Poitiers University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Poitiers University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2012"
    }
}